Inactive Instrument

ERBA Diagnostics, Inc.

Equities

ERBA

US29490B1017

Medical Equipment, Supplies & Distribution

ERBA Diagnostics, Inc. Provides Earnings Guidance for the Year Ended December 31, 2012

April 17, 2013 at 01:41 pm

ERBA Diagnostics, Inc. provided earnings guidance for the year ended December 31, 2012. For the period, the company expects revenues of approximately $19,500,000 compared to revenues of $16,759,773 for the year ended December 31, 2011. Net loss of approximately $1,100,000 compared to net loss of $3,297,343 for the year ended December 31, 2011.

Latest news about ERBA Diagnostics, Inc.

Inovabio S.r.l., Redix Consulting Limited Liability Company and Kolodziejczyk Waldemar acquired Delta Bialogiclas Srl from ERBA Diagnostics, Inc. for €0.05 million.	05/07/20	CI
ERBA Diagnostics, Inc. Appoints Jean Felix Lacroix as Chief Financial Officer and Treasurer, Principal Financial Officer and Principal Accounting Officer	23/04/19	CI
ERBA Diagnostics, Inc. announced that it expects to receive $8 million in funding from ERBA Diagnostics Mannheim GmbH	30/07/18	CI
ERBA Diagnostics, Inc. announced that it has received $0.75 million in funding from ERBA Diagnostics Mannheim GmbH	17/04/18	CI
Erba Diagnostics Inc. Enters into a Promissory Note in Favor of Erba Diagnostics Mannheim GmbH	01/03/18	CI
ERBA Diagnostics, Inc. announced that it has received $0.25 million in funding from ERBA Diagnostics Mannheim GmbH	27/09/17	CI
ERBA Diagnostics, Inc. Announces Management Changes, Effective August 1, 2017	25/07/17	CI
ERBA Diagnostics, Inc. Announces Board Changes	17/07/17	CI
ERBA Diagnostics, Inc. Announces Resignation of Ernesina Scala as Chief Financial Officer	22/06/17	CI
Hayden Jeffreys to Resign as Interim Chief Executive Officer and Member of Board of Directors of ERBA Diagnostics, Inc., Effective September 11, 2017	16/06/17	CI
ERBA Diagnostics, Inc. announced that it expects to receive $0.75 million in funding from ERBA Diagnostics Mannheim GmbH	15/06/17	CI
ERBA Diagnostics, Inc. Secures Revolving Credit Facility of Up to $5,000,000 from Citibank, N.A	19/05/17	CI
ERBA Diagnostics, Inc. Enters into Amended and Restated Promissory Note with Citibank	30/12/16	CI
ERBA Diagnostics, Inc. Enters into Promissory Note for an Unsecured Loan of Up to $1,000,000	02/12/16	CI
ERBA Diagnostics, Inc. Announces Management Changes	29/11/16	CI
ERBA Diagnostics, Inc. announced that it has received $0.4 million in funding from ERBA Diagnostics Mannheim GmbH	27/11/16	CI
ERBA Diagnostics, Inc.(OTCPK:ERBA) dropped from S&P TMI Index	04/10/16	CI
ERBA Diagnostics, Inc. Announces Management Changes	31/05/16	CI
ERBA Diagnostics, Inc. Changes in Terms Agreement with Citibank	23/02/16	CI
ERBA Diagnostics, Inc. announced that it has received $15 million in funding from ERBA Diagnostics Mannheim GmbH.	28/12/15	CI
ERBA Diagnostics Seeks Acquisition	30/11/15	CI
ERBA Diagnostics, Inc. to Launch Lisa XL System in Europe and International Markets	15/11/15	CI
ERBA Diagnostics, Inc. Enters into Business Loan Agreement with Citibank, N.A	22/09/15	CI
ERBA Diagnostics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	08/08/15	CI
ERBA Diagnostics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	26/06/15	CI

Chart ERBA Diagnostics, Inc.

Duration

Period

More charts

Company Profile

ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The Company's segments include Domestic and European. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations. The European region contains its subsidiary located in Italy. Its tests are based on a range of technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology and cell separation, as well as high performance liquid chromatography (HPLC) separations, all of which are clinical testing methodologies used across the world. It also designs and manufactures laboratory instruments that perform the tests.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-7.16%	178B
MEDTRONIC PLC	-1.23%	107B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.23B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+9.25%	42.5B
TERUMO CORPORATION	+15.97%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	23.69B

Other Medical Equipment, Supplies & Distribution